Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 365

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 7
Chunk 365
---
    1,384,480

    727,905

    Loss from operations
     
    $
    (691,082
    )
     
    $
    (196,083
    )

    Interest income

    11,084

    7,601

    Interest expense

    (53,653
    )

    (46,869
    )

    Other income, net

    32,336

    21,822

    Loss before provision for income taxes

    (701,315
    )

    (213,529
    )

    Provision for income taxes

    (266
    )

    (288
    )

    Losses from equity method investments

    (4,228
    )

    (301
    )

    Net Loss
     
    $
    (705,809
    )
     
    $
    (214,118
    )

Comparison of the years ended December 31, 2024 and 2023

Revenue 

    Year Ended December 31,

    2024

    2023

    $ Change

    % Change

    (in thousands, except percentages)

    Genomics
     
    $
    451,749

    $
    363,022

    $
    88,727

    24
    %

    Data and services

    241,649

    168,800

    72,849

    43
    %

    Total Net Revenue
     
    $
    693,398

    $
    531,822

    $
    161,576

    30
    %

The increase in revenue for the year ended December 31, 2024, compared to the same period in 2023, was due to increased volume and reimbursement of clinical oncology tests performed in Genomics and increased data deliveries in our Data and Services product line. 

Genomics 

The increase in Genomics revenue for the year ended December 31, 2024, compared to the same period in 2023, was primarily due to an increase in the number of oncology NGS tests, which increased from approximately 218,700 tests for the year ended December 31, 2023 to approximately 270,800 tests for the year ended December 31, 2024. Additionally, there was an increase in average revenue per NGS oncology test, which increased from approximately $1,450 per test for the